PKD2
MCID: PLY060
MIFTS: 51

Polycystic Kidney Disease 2 (PKD2) malady

Categories: Genetic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Polycystic Kidney Disease 2

About this section

Aliases & Descriptions for Polycystic Kidney Disease 2:

Name: Polycystic Kidney Disease 2 52 11 70 27 12 13
Pkd2 11 70
Polycystic Kidney Type 2 Autosomal Dominant Disease 50
Autosomal Dominant Polycystic Kidney Disease 2 70
Polycystic Kidney Disease, Adult, Type Ii 11
Polycystic Kidney Disease Adult Type Ii 70
 
Adult Polycystic Kidney Disease Type 2 70
Polycystic Kidney Disease, Type 2 68
Adpkd2 70
Apkd2 11
Pkd-2 70

Characteristics:

HPO:

64
polycystic kidney disease 2:
Inheritance: autosomal dominant inheritance

Classifications:



External Ids:

OMIM52 613095
Disease Ontology11 DOID:0110859
MedGen37 C2751306

Summaries for Polycystic Kidney Disease 2

About this section
UniProtKB/Swiss-Prot:70 Polycystic kidney disease 2: A disorder characterized by progressive formation and enlargement of cysts in both kidneys, typically leading to end-stage renal disease in adult life. Cysts also occurs in the liver and other organs. It represents approximately 15% of the cases of autosomal dominant polycystic kidney disease. PKD2 is clinically milder than PKD1 but it has a deleterious impact on overall life expectancy.

MalaCards based summary: Polycystic Kidney Disease 2, also known as PKD2, is related to polycystic kidney disease 2, autosomal dominant and kidney disease, and has symptoms including renal insufficiency and polycystic kidney dysplasia. An important gene associated with Polycystic Kidney Disease 2 is PKD2 (Polycystin 2, Transient Receptor Potential Cation Channel), and among its related pathways are Ca, cAMP and Lipid Signaling and Transcription_Transcription factor Tubby signaling pathways. Affiliated tissues include kidney and liver, and related mouse phenotypes are Decreased human cytomegalovirus (HCMV) strain AD169 replication and Increased cell migration.

Disease Ontology:11 A autosomal dominant polycystic kidney disease that has material basis in autosomal dominant inheritance of mutation in the PKD2 gene on chromosome 4q22.1.

Description from OMIM:52 613095

Related Diseases for Polycystic Kidney Disease 2

About this section

Diseases in the Polycystic Kidney Disease family:

polycystic kidney disease 2 Polycystic Kidney Disease, Adult Type I
Polycystic Kidney Disease 3 Autosomal Dominant Polycystic Kidney Disease
Polycystic Kidney Disease 1, Autosomal Dominant Polycystic Kidney Disease 2, Autosomal Dominant

Diseases related to Polycystic Kidney Disease 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 19)
idRelated DiseaseScoreTop Affiliating Genes
1polycystic kidney disease 2, autosomal dominant12.0
2kidney disease10.3
3polycystic kidney disease10.3
4dicer1-related disorders10.1PKD1, PKHD1
5autosomal dominant polycystic kidney disease10.0
6inclusion body myopathy with paget disease of bone and frontotemporal dementia10.0PKD1, PKHD1
7kidney papillary necrosis10.0PKD1, PKD2, PKHD1
8atrophic vulva9.9PKDREJ, PKHD1, PRKD1
9holoprosencephaly 89.9PKD1, PKD2, PKD3, PKDREJ, PRKD1
10t-cell large granular lymphocyte leukemia9.7PKD1, PKD2, PKDREJ, PKHD1, PRKD1
11anemia, hemolytic, rh-null, regulator type9.7PKD1, PKD2, PKHD1, PRKCSH, PRKD1
12polycystic liver disease9.7
13liver disease9.7
14psoriasis susceptibility 139.5PKD1, PKD2, PKHD1, PRKCSH, PRKD1, SEC63
15lung giant cell carcinoma9.5PKD1, PKD1L1, PKD1L3, PKD2, PKD2L1, PKD2L2
16gastrointestinal lymphoma9.4PKD1, PKD2, PKD2L1, PKD3, PKDREJ, PKHD1
171q21.1 recurrent microdeletion9.3HAX1, PKD1, PKD1L1, PKD1L3, PKD2, PKD2L1
18charcot-marie-tooth disease, type 1c8.5PKD1, PKD1L1, PKD2, PKD2L1, PKD2L2, PKDREJ
19orofacial cleft 48.0HAX1, MIR17, PDK2, PKD1, PKD1L1, PKD1L3

Graphical network of diseases related to Polycystic Kidney Disease 2:



Diseases related to polycystic kidney disease 2

Symptoms & Phenotypes for Polycystic Kidney Disease 2

About this section


Clinical features from OMIM:

613095

Human phenotypes related to Polycystic Kidney Disease 2:

 64
id Description HPO Frequency HPO Source Accession
1 renal insufficiency64 HP:0000083
2 polycystic kidney dysplasia64 HP:0000113

GenomeRNAi Phenotypes related to Polycystic Kidney Disease 2 according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00248-A9.9PKD2L1, PKD2L2, PRKD1, PRKD3
2GR00055-A-39.4PKD1, PKD2, PRKD2, PRKD3

MGI Mouse Phenotypes related to Polycystic Kidney Disease 2 according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053678.0PKD1, PKD1L1, PKD2, PKHD1, PRKCSH, SEC63

Drugs & Therapeutics for Polycystic Kidney Disease 2

About this section

Drugs for Polycystic Kidney Disease 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 169)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Sirolimusapproved, investigationalPhase 4, Phase 2, Phase 3, Phase 1194053123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
2
EverolimusapprovedPhase 4, Phase 2, Phase 3, Phase 11940159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
3
Miconazoleapproved, investigational, vet_approvedPhase 4, Phase 2, Phase 3, Phase 1370622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
4
CilnidipineapprovedPhase 4, Phase 28132203-70-45282138
Synonyms:
(+-)-(E)-Cinnamyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl (2E)-3-phenyl-2-propenyl ester
132203-70-4
2-methoxyethyl (2E)-3-phenylprop-2-en-1-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
3-O-(2-methoxyethyl) 5-O-[(E)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
AC-270
AC1NQZJB
Atelec
Atelec (TN)
BRD-A07875874-001-01-6
Bio-0164
C1493_SIGMA
C27H28N2O7
CHEBI:31399
CHEBI:438069
CHEMBL452076
CID5282138
 
Cilnidipine (JAN/INN)
Cilnidipine [INN]
Cinaldipine
Cinalong
D01173
FRC 8653
FRC-8653
HMS2089J07
I06-0491
LS-131293
MolPort-003-845-950
NCGC00162150-01
NCGC00162150-02
NCGC00162150-03
S1293_Selleck
STK623341
Siscard
cilnidipine
5
CandesartanapprovedPhase 4, Phase 2157139481-59-72541
Synonyms:
139481-59-7
2-(ethyloxy)-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid
2-Ethoxy-1-(P-(O-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylic acid
2-Ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylic acid
2-Ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid
2-Ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4ethyl]}-1H-benzimidazole-7-carboxylic acid
2-Ethoxy-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl] methyl]-3H-benzoimidazole-4-carboxylic acid
2-ethoxy-1-({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl)-1H-benzimidazole-7-carboxylic acid
2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid
2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4ethyl}-1H-benzimidazole-7-carboxylic acid
2-ethoxy-3-[[4-[2-(1h-tetrazol-5-yl)phenyl]phenyl]methyl]-3h-benzoimidazole-4-carboxylic acid
2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid
2-ethoxy-7-carboxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methylbenzimidazole
AC-203
AC1L1DWT
Amias
Atacand
Atacand, Blopress, Amias, Ratacand,Candesartan
BIDD:GT0350
Blopress
Blopress (TN)
C07468
C081643
C24H20N6O3
CHEBI:216848
 
CHEBI:3347
CHEMBL1016
CID2541
CV 11974
CV-11974
CV11974
Candesartan (USAN/INN)
Candesartan [BAN]
Candesartan [USAN:INN]
Candesartan cilexetil
D00522
DB00796
FT-0083585
HMS2089M22
HSDB 7520
I01-0374
KS-5003
L000156
LS-32740
MolPort-003-845-570
MolPort-005-943-739
NCGC00167474-01
Ratacand
S1578_Selleck
TL8000897
UNII-S8Q36MD2XX
candesartan
6
Tacrolimusapproved, investigationalPhase 41102104987-11-3445643, 439492
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
AKOS005145901
Advagraf
Ambap104987-11-3
Ambap5429
Anhydrous tacrolimus
BCBcMAP01_000194
BRD-K35452788-001-02-1
BSPBio-001279
BSPBio_001279
Bio-0921
Bio2_000470
Bio2_000950
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
CPD-10016
CPD000466356
D08556
DB00864
DivK1c_001040
FK 506
FK-506
FK5
FK506
FR 900506
FR-900506
 
FR900506
FT-0082660
Fk-506
Fujimycin
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
IDI1_001040
IDI1_002225
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus (anhydrous)
Tacrolimus anhydrous
Tacrolimus hydrate
Tacrolimus, anhydrous
Tsukubaenolide
UNII-Y5L2157C4J
nchembio.2007.23-comp2
tacrolimus
tacrolimus hydrate
7
Prednisoneapproved, vet_approvedPhase 4139853-03-25865
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
ACon0_000082
ACon1_000297
AI3-52939
Adasone
Ancortone
Apo-Prednisone
Apo-prednisone
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
Betapar
Bicortone
Bio-0649
C07370
C21H26O5
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
CPD001227202
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
DB00635
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta E.
Delta-Cortelan
Delta-Dome
Delta-cortelan
Delta-cortisone
Delta-cortone
Delta-dome
Deltacortene
Deltacortisone
Deltacortone
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Di-Adreson
Diadreson
EINECS 200-160-3
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fernisone
Fiasone
HMS1568O15
HMS2090J13
HSDB 3168
Hostacortin
In-Sone
Incocortyl
 
Juvason
Kortancyl
LMST02030180
LS-1325
Liquid Pred
Lisacort
Lodotra
MEGxm0_000443
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
Me-Korti
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI-C04897
NCI60_000008
NSC 10023
NSC10023
Nisona
Nizon
Novoprednisone
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
PRD
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Precort
Predeltin
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Prednison
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone Intensol
Prednisone [INN:BAN]
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Prestwick_405
Pronison
Pronisone
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
SK-Prednisone
SMR000718760
SMR001227202
SPBio_002214
Servisone
Sone
Sterapred
Supercortil
U 6020
UNII-VB0R961HZT
Ultracorten
Ultracortene
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Winpred
Wojtab
ZINC03875357
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
delta cortelan
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
delta-Cortisone
delta-Cortone
8
Methylprednisoloneapproved, vet_approvedPhase 4119383-43-26741
Synonyms:
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6-Methylprednisolone
6-alpha-Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
AC1L1N7A
Artisone-Wyeth
Artisone-wyeth
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
Besonia
Bio-0658
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
LMST02030178
LS-118498
Lemod
M0639_SIGMA
M1665
MEPRDL
MLS000028541
MLS001148159
MLS002207191
Medesone
Medixon
Medlone 21
 
Medrate
Medrol
Medrol (TN)
Medrol Adt Pak
Medrol Dosepak
Medrol adt pak
Medrol dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [DCIT]
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
NSC-19987
NSC19987
Nirypan
Noretona
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Prestwick_622
Promacortine
Reactenol
S1733_Selleck
SAM002589984
SMR000058330
SPBio_002377
Sieropresol
Solomet
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
delta(1)-6alpha-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
methylprednisolone
methylprenisolone
9
Mycophenolate mofetilapproved, investigationalPhase 4952128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
10
Mycophenolic acidapprovedPhase 495224280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
 
Melbex
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolsäure
Myfortic
11
Prednisoloneapproved, vet_approvedPhase 4119350-24-85755
Synonyms:
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bio-0666
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
CO-Hydeltra
CPD000718761
Co-Hydeltra
Codelcortone
Cordrol
Cortalone
Cotogesic
Cotolone
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
Delta(1)-dehydrohydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Delta-Ef-Cortelan
Delta-Stab
Delta-stab
Deltacortenol
Deltacortril
Deltacortril Enteric
Deltahydrocortisone
Deltasolone
Deltisilone
Depo-Medrol
Derpo PD
Derpo Pd
Dexa-Cortidelt Hostacortin H
Dexa-Cortidelt hostacortin H
Di Adreson F
Di-Adreson F
Di-Adreson-F
Di-adreson F
DiAdresonF
Dicortol
Donisolone
Dydeltrone
EINECS 200-021-7
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
HSDB 3385
Hostacortin H
Hydeltra
Hydeltra-Tba
Hydeltrasol
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
I-Pred
Inflamase Forte
Inflamase Mild
K 1557
Key-Pred
Klismacort
LMST02030179
LS-7669
Lentosone
Lite Pred
M-Predrol
 
MLS001304083
MLS002154250
MLS002207037
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone Acetate
Meti-Derm
Meticortelone
Metreton
MolPort-002-507-147
NCGC00179649-01
NSC 9120
NSC9120
NSC9900
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
PRDL
PRED-G
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Predni-Dome
Prednicen
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone (JP15/USP/INN)
Prednisolone (anhydrous)
Prednisolone Acetate
Prednisolone Sodium Phosphate
Prednisolone Tebutate
Prednisolone [INN:BAN:JAN]
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Prestwick_404
Rolisone
S1737_Selleck
SAM002264639
SMR000718761
SPBio_002367
Scherisolon
Solone
Steran
Sterane
Sterolone
Supercortisol
UNII-9PHQ9Y1OLM
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
Ultracortene-hydrogen
ZINC03833821
component of Ataraxoid
component of K-Predne-Dome
delta(1)-Cortisol
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
prednisolone
12Anti-Infective AgentsPhase 4, Phase 2, Phase 3, Phase 122062
13Adrenergic AgentsPhase 45352
14Antibiotics, AntitubercularPhase 4, Phase 2, Phase 3, Phase 17180
15Immunosuppressive AgentsPhase 4, Phase 2, Phase 3, Phase 113086
16Antifungal AgentsPhase 4, Phase 2, Phase 3, Phase 13696
17Angiotensin II Type 1 Receptor BlockersPhase 4, Phase 31091
18Angiotensin Receptor AntagonistsPhase 4, Phase 3, Phase 21191
19
Angiotensin IIPhase 4, Phase 3, Phase 2117868521-88-0, 11128-99-765143, 172198
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
Ang II
Angiotensin 2
Angiotensin II (human)
 
Angiotensin II (mouse)
Angiotonin
Asp-arg-val-TYR-ile-his-pro-phe
Human angiotensin II
Hypertensin
Ile(5)-angiotensin II
20Adrenergic AntagonistsPhase 41573
21Adrenergic alpha-AntagonistsPhase 4739
22Angiotensin-Converting Enzyme InhibitorsPhase 4, Phase 3, Phase 2724
23AngiotensinogenPhase 4, Phase 3, Phase 21177
24
Candesartan cilexetilPhase 4, Phase 2157145040-37-52540
Synonyms:
(+-)-1-Hydroxyethyl 2-ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylate, cyclohexyl carbonate (ester)
1-(cyclohexylocarbonyloxy)ethyl-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-1H-benzimidazole-7-carboxylate
1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate
1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 2-(ethyloxy)-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate
145040-37-5
1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester
2-Ethoxy-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester
2-ethoxy-3-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-benzoimidazole-4-carboxylic acid 1-cyclohe
AC-204
AC1L1DWQ
ATACAND HCT
Almirall brand of candesartan cilexetil
Amias
Astra brand of candesartan cilexetil
AstraZeneca brand of candesartan cilexetil
Atacand
Atacand (TN)
BRD-A65671304-001-02-6
BSPBio_002691
C07709
C077793
C33H34N6O6
CHEBI:216349
CHEMBL1014
CID2540
Candesartan cilexetil
Candesartan cilexetil (JAN/USAN)
Candesartan cilexetil [USAN]
Candesartan hexetil
D00626
FT-0082579
H212/91
 
HMS1922J09
HMS2093E20
I06-0090
KBio2_002187
KBio2_004755
KBio2_007323
KBio3_001911
KBioGR_001607
KBioSS_002187
Kenzen
L006257
LS-32741
MolPort-003-666-552
NCGC00095123-01
NCGC00095123-02
NCGC00095123-03
Parapres
Promed brand of candesartan cilexetil
Racanda
SPBio_000349
SPECTRUM1504261
ST51052687
Spectrum2_000485
Spectrum3_000996
Spectrum4_001124
Spectrum5_001462
Spectrum_001707
TCV 116
TCV-116
TL8000995
Takeda brand of candesartan cilexetil
UNII-R85M2X0D68
candesartan cilexitil
25Anti-Bacterial AgentsPhase 4, Phase 2, Phase 3, Phase 111226
26Calcium, DietaryPhase 4, Phase 3, Phase 2, Early Phase 15713
27calcium channel blockersPhase 4, Phase 3, Phase 21985
28Antihypertensive AgentsPhase 4, Phase 3, Phase 24207
29Gastrointestinal AgentsPhase 4, Phase 2, Phase 3, Phase 18402
30HormonesPhase 4, Phase 3, Phase 2, Early Phase 114415
31Protective AgentsPhase 4, Phase 3, Phase 27443
32Autonomic AgentsPhase 4, Phase 210150
33Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 2, Early Phase 113168
34Hormone AntagonistsPhase 4, Phase 3, Phase 2, Early Phase 113180
35Peripheral Nervous System AgentsPhase 4, Phase 223689
36Antineoplastic Agents, HormonalPhase 4, Phase 2, Phase 3, Early Phase 15592
37Antirheumatic AgentsPhase 410956
38
CurcuminPhase 4146458-37-7969516
Synonyms:
1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione
1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione
1,9-Bis(4-hydroxy-3-methoxyphenyl)-2,7-nonadiene-4,6-dione
C.I. Natural Yellow 3
CI Natural Yellow 3
Cucurmin
Curcuma
Curcumin
Curcumin I
Diferaloylmethane
Diferuloylmethane
Gelbwurz
Golden seal
Haidr
Halad
Haldar
Halud
Hydrastis
 
Indian saffron
Indian turmeric
Kacha haldi
Kurkumin [czech]
Merita earth
Natural yellow 3
Orange root
Safran D'inde
Souchet
Terra merita
Tumeric yellow
Turmeric
Turmeric (>98% curcurmin)
Turmeric oleoresin (79%-85% curcumin)
Turmeric yellow
Yellow ginger
Yellow puccoon
Yellow root
Yo-kin
Zlut prirodni 3 [Czech]
39Analgesics, Non-NarcoticPhase 46501
40AnalgesicsPhase 411733
41Anti-Inflammatory Agents, Non-SteroidalPhase 44443
42Anti-Inflammatory AgentsPhase 410729
43Prednisolone phosphatePhase 41193
44Prednisolone hemisuccinatePhase 41193
45Antilymphocyte SerumPhase 4408
46glucocorticoidsPhase 45103
47Methylprednisolone acetatePhase 41193
48Prednisolone acetatePhase 41193
49AntiemeticsPhase 44022
50Methylprednisolone HemisuccinatePhase 41193

Interventional clinical trials:

(show top 50)    (show all 82)
idNameStatusNCT IDPhase
1CCB Safety Study in Treatment of Hypertension of ADPKDUnknown statusNCT00541853Phase 4
2Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT00414440Phase 4
3Weight Loss Improves Renal HemodynamicsCompletedNCT01356394Phase 4
4Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKDRecruitingNCT02494141Phase 4
5Prednisone Withdrawal Versus Prednisone Maintenance After Kidney TransplantTerminatedNCT00596947Phase 4
6Sirolimus for Massive Polycystic LiverUnknown statusNCT01680250Phase 2, Phase 3
7Open-Label Extension of LOCKCYST TrialUnknown statusNCT00771888Phase 2, Phase 3
8A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]CompletedNCT01022424Phase 3
9Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT02225860Phase 2, Phase 3
10Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT00456365Phase 3
11Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT00346918Phase 3
12Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up StudyCompletedNCT00309283Phase 3
13HALT Progression of Polycystic Kidney Disease (HALT PKD) Study ACompletedNCT00283686Phase 3
14Effects of Somatostatin on ADPKD HeartCompletedNCT02119013Phase 2, Phase 3
15HALT Progression of Polycystic Kidney Disease (HALT PKD) Study BCompletedNCT01885559Phase 3
16Effects of Somatostatin on Liver in ADPKDCompletedNCT02119052Phase 2, Phase 3
17Lanreotide as Treatment of Polycystic LiversCompletedNCT00565097Phase 2, Phase 3
18Octreotide in Severe Polycystic Liver DiseaseCompletedNCT00426153Phase 2, Phase 3
19Open-Label Tolvaptan Study in Subjects With ADPKDCompletedNCT01214421Phase 3
20Tolvaptan Phase 3 Efficacy and Safety Study in ADPKDCompletedNCT00428948Phase 3
21Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver DiseaseCompletedNCT01315795Phase 2, Phase 3
22Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney DiseaseRecruitingNCT02055079Phase 3
23Lanreotide In Polycystic Kidney Disease StudyRecruitingNCT02127437Phase 3
24Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS)RecruitingNCT01733459Phase 3
25Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal InsufficiencyActive, not recruitingNCT01377246Phase 3
26Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney DiseaseActive, not recruitingNCT02160145Phase 3
27Study of Lanreotide to Treat Polycystic Kidney DiseaseActive, not recruitingNCT01616927Phase 3
28Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney DiseaseEnrolling by invitationNCT02251275Phase 3
29Everolimus on CKD Progression in ADPKD PatientsTerminatedNCT01009957Phase 2, Phase 3
30Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal InsufficiencyTerminatedNCT01223755Phase 2, Phase 3
31Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to TherapyTerminatedNCT00920309Phase 2, Phase 3
32Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pain StudyUnknown statusNCT00571909Phase 2
33Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)Unknown statusNCT00890279Phase 2
34Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression ControlUnknown statusNCT01932450Phase 2
35Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and SafetyCompletedNCT00491517Phase 2
36Bosutinib For Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT01233869Phase 2
37Effect of the Aquaretic Tolvaptan on Nitric Oxide SystemCompletedNCT02527863Phase 2
38Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT00286156Phase 1, Phase 2
39Tolvaptan Open-Label Pilot Efficacy, Tolerability and Safety Study in ADPKDCompletedNCT00413777Phase 2
408-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT01451827Phase 2
41Short-Term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT01336972Phase 2
42Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney DiseaseCompletedNCT02140814Phase 2
43A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]CompletedNCT00841568Phase 2
44Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKDCompletedNCT01210560Phase 2
45Ursodeoxycholic Acid as Treatment for Polycystic Liver DiseaseCompletedNCT02021110Phase 2
46Pilot Study of Niacinamide in Polycystic Kidney Disease (NIAC-PKD2)RecruitingNCT02558595Phase 2
47Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney DiseaseRecruitingNCT02656017Phase 2
48Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney DiseaseRecruitingNCT02697617Phase 2
49Feasibility Study of Metformin Therapy in ADPKDRecruitingNCT02903511Phase 2
50A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)Active, not recruitingNCT01559363Phase 1, Phase 2

Search NIH Clinical Center for Polycystic Kidney Disease 2

Genetic Tests for Polycystic Kidney Disease 2

About this section

Genetic tests related to Polycystic Kidney Disease 2:

id Genetic test Affiliating Genes
1 Polycystic Kidney Disease 227

Anatomical Context for Polycystic Kidney Disease 2

About this section

MalaCards organs/tissues related to Polycystic Kidney Disease 2:

36
Kidney, Liver

Publications for Polycystic Kidney Disease 2

About this section

Articles related to Polycystic Kidney Disease 2:

(show all 13)
idTitleAuthorsYear
1
Characterization of the polycystic kidney disease 2 gene promoter. (25173570)
2014
2
Multiple postnatal craniofacial anomalies are characterized by conditional loss of polycystic kidney disease 2 (Pkd2). (23390131)
2013
3
Construction of a transgenic pig model overexpressing polycystic kidney disease 2 (PKD2) gene. (23315160)
2013
4
Polymorphisms of four microsatellite markers tightly linked with polycystic kidney disease 2 gene in Chinese]. (11836683)
2002
5
Mutations of the human polycystic kidney disease 2 (PKD2) gene. (11438989)
2001
6
A novel frameshift mutation (2436insT) produces an immediate stop codon in the autosomal dominant polycystic kidney disease 2 (PKD2) gene. (10727541)
2000
7
Polymorphisms in the human autosomal dominant polycystic kidney disease 2 (PKD2) gene. (10369752)
1999
8
Mutations in autosomal dominant polycystic kidney disease 2 gene: Reduced expression of PKD2 protein in lymphoblastoid cells. (10213643)
1999
9
A novel frameshift mutation induced by an adenosine insertion in the polycystic kidney disease 2 (PKD2) gene. (9573526)
1998
10
A translation frameshift mutation induced by a cytosine insertion in the polycystic kidney disease 2 gene (PDK2). (9175744)
1997
11
Novel stop and frameshifting mutations in the autosomal dominant polycystic kidney disease 2 (PKD2) gene. (9402976)
1997
12
Characterization of the exon structure of the polycystic kidney disease 2 gene (PKD2). (9286709)
1997
13
Isolated polycystic liver disease as a distinct genetic disease, unlinked to polycystic kidney disease 1 and polycystic kidney disease 2. (8591848)
1996

Variations for Polycystic Kidney Disease 2

About this section

UniProtKB/Swiss-Prot genetic disease variations for Polycystic Kidney Disease 2:

70
id Symbol AA change Variation ID SNP ID
1PKD2p.Trp414GlyVAR_009195
2PKD2p.Ala356ProVAR_011073
3PKD2p.Arg306GlnVAR_058822
4PKD2p.Arg322GlnVAR_058823rs145877597
5PKD2p.Arg322TrpVAR_058824
6PKD2p.Arg420GlyVAR_058825
7PKD2p.Asp511ValVAR_058827rs121918043
8PKD2p.Cys632ArgVAR_058828
9PKD2p.Arg807GlnVAR_058830rs147654263
10PKD2p.Ala384ProVAR_064394

Clinvar genetic disease variations for Polycystic Kidney Disease 2:

5 (show all 13)
id Gene Variation Type Significance SNP ID Assembly Location
1PKD2NM_ 000297.3(PKD2): c.1139G> A (p.Trp380Ter)SNVPathogenicrs121918039GRCh37Chr 4, 88964429: 88964429
2PKD2NM_ 000297.3(PKD2): c.2224C> T (p.Arg742Ter)SNVPathogenicrs121918040GRCh37Chr 4, 88986631: 88986631
3PKD2NM_ 000297.3(PKD2): c.1213C> T (p.Gln405Ter)SNVPathogenicrs121918041GRCh37Chr 4, 88964503: 88964503
4PKD2PKD2, 1-BP INS, 693CinsertionPathogenic
5PKD2NM_ 000297.3(PKD2): c.1390C> T (p.Arg464Ter)SNVPathogenicrs121918042GRCh38Chr 4, 88046712: 88046712
6PKD2PKD2, 1-BP INS, 2160AinsertionPathogenic
7PKD2PKD2, 1-BP INS, 197_ 203CinsertionPathogenic
8PKD2NM_ 000297.3(PKD2): c.1532A> T (p.Asp511Val)SNVPathogenicrs121918043GRCh37Chr 4, 88968006: 88968006
9PKD2PKD2, 2-BP DEL/1-BP INS, NT1934indelPathogenic
10PKD2NM_ 000297.3(PKD2): c.916C> T (p.Arg306Ter)SNVPathogenicrs200001068GRCh37Chr 4, 88959475: 88959475
11PKD2NM_ 000297.3(PKD2): c.691dupC (p.Leu231Profs)duplicationLikely pathogenicGRCh38Chr 4, 88019553: 88019553
12PKD2NC_ 000004.11: g.88957372-?_ 89042944+?dupduplicationPathogenicGRCh37Chr 4, 88957372: 88957372
13PKD2NM_ 000297.3(PKD2): c.305_ 306insGAG (p.Glu102_ Val103insArg)insertionPathogenicrs398122932GRCh37Chr 4, 88929190: 88929191

Expression for genes affiliated with Polycystic Kidney Disease 2

About this section
Search GEO for disease gene expression data for Polycystic Kidney Disease 2.

Pathways for genes affiliated with Polycystic Kidney Disease 2

About this section

Pathways related to Polycystic Kidney Disease 2 according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
18.8PRKD1, PRKD2, PRKD3
28.8PRKD1, PRKD2, PRKD3
38.8PRKD1, PRKD2, PRKD3

GO Terms for genes affiliated with Polycystic Kidney Disease 2

About this section

Cellular components related to Polycystic Kidney Disease 2 according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cation channel complexGO:003470310.7PKD1L3, PKD2L1
2calcium channel complexGO:003470410.6PKD1L1, PKD2L1
3polycystin complexGO:000213310.0PKD1, PKD2
4ciliary membraneGO:006017010.0PKD1, PKD1L1, PKD2, PKD2L1
5cell projectionGO:00429959.6PKD1, PKD1L1, PKD2, PKD2L1, PKHD1
6non-motile ciliumGO:00977309.5PKD1L1, PKD2, PKD2L1
7ciliumGO:00059299.3PKD1, PKD1L1, PKD2, PKD2L1, PKHD1

Biological processes related to Polycystic Kidney Disease 2 according to GeneCards Suite gene sharing:

(show all 31)
idNameGO IDScoreTop Affiliating Genes
1cytoplasmic sequestering of transcription factorGO:004299410.8PKD1, PKD2
2embryonic placenta developmentGO:000189210.8PKD1, PKD2
3mesonephric duct developmentGO:007217710.8PKD1, PKD2
4mesonephric tubule developmentGO:007216410.8PKD1, PKD2
5metanephric ascending thin limb developmentGO:007221810.8PKD1, PKD2
6placenta blood vessel developmentGO:006067410.8PKD1, PKD2
7positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycleGO:003165910.8PKD1, PKD2
8cellular response to acidic pHGO:007146810.7PKD1L3, PKD2L1
9detection of chemical stimulus involved in sensory perception of sour tasteGO:000158110.7PKD1L3, PKD2L1
10sensory perception of sour tasteGO:005091510.7PKD1L3, PKD2L1
11detection of nodal flowGO:000312710.6PKD1L1, PKD2
12single organismal cell-cell adhesionGO:001633710.1PKD1, PKD1L1, PKHD1
13cellular response to vascular endothelial growth factor stimulusGO:003592410.1PRKD1, PRKD2
14positive regulation of blood vessel endothelial cell migrationGO:004353610.1PRKD1, PRKD2
15positive regulation of CREB transcription factor activityGO:003279310.1PRKD1, PRKD2
16positive regulation of endothelial cell chemotaxisGO:200102810.1PRKD1, PRKD2
17positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathwayGO:003803310.1PRKD1, PRKD2
18positive regulation of histone deacetylase activityGO:190172710.1PRKD1, PRKD2
19kidney developmentGO:000182210.0PKD1, PKD1L3, PKD2, PKHD1
20calcium ion transportGO:00068169.9PKD1, PKD1L1, PKD1L3, PKD2, PKD2L1
21nitrogen compound metabolic processGO:00068079.8PKD1, PRKCSH, SEC63
22peptidyl-serine phosphorylationGO:00181059.8PKD1, PRKD1, PRKD2
23positive regulation of peptidyl-serine phosphorylationGO:00331389.8HAX1, PRKD1, PRKD2
24liver developmentGO:00018899.6PKD1, PKD2, PRKCSH, SEC63
25renal system developmentGO:00720019.6PKD1, PKD2, PRKCSH, SEC63
26protein kinase D signalingGO:00897009.6PRKD1, PRKD2, PRKD3
27sphingolipid biosynthetic processGO:00301489.5PRKD1, PRKD2, PRKD3
28ion transportGO:00068119.5PKD1L1, PKD1L3, PKD2, PKD2L1, PKD2L2, PKDREJ
29calcium ion transmembrane transportGO:00705889.3PKD1, PKD1L1, PKD1L3, PKD2, PKD2L1, PKD2L2
30detection of mechanical stimulusGO:00509829.3PKD1, PKD1L1, PKD1L3, PKD2, PKD2L1, PKD2L2
31transportGO:00068108.2PKD1L1, PKD1L3, PKD2, PKD2L1, PKD2L2, PKDREJ

Molecular functions related to Polycystic Kidney Disease 2 according to GeneCards Suite gene sharing:

(show all 8)
idNameGO IDScoreTop Affiliating Genes
1alpha-actinin bindingGO:005139310.7PKD2, PKD2L1
2cation transmembrane transporter activityGO:000832410.5PKD1L3, PKD2L1
3muscle alpha-actinin bindingGO:005137110.4PKD2, PKD2L1
4sour taste receptor activityGO:003304010.0PKD1L3, PKD2L1
5ion channel bindingGO:00443259.9PKD1, PKD2, PRKCSH
6calcium ion bindingGO:00055099.5PKD2, PKD2L1, PKD2L2, PKDREJ, PRKCSH
7calcium channel activityGO:00052629.2PKD1, PKD1L1, PKD1L3, PKD2, PKD2L1, PKD2L2
8protein kinase C activityGO:00046978.7PRKD1, PRKD2, PRKD3

Sources for Polycystic Kidney Disease 2

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet